EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

HER2 in mullerian malignancies: diagnostic challenges and the emerging HER2-low paradigm

Sana Ahuja, Charanjeet Ahluwalia

Obstetrics & Gynecology Science · 15.11.2026 · 69 (6) · 418-430

DOI: 10.5468/ogs.26195 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Obstetrics & Gynecology Science, erschienen am 15.11.2026. Verfasst von Sana Ahuja und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The role of human epidermal growth factor receptor 2 (HER2) in gynecological oncology has evolved from a histotype-restricted biomarker to a central component of molecular stratification, particularly within the p53-aberrant subgroup of Müllerian malignancies. HER2 amplification and overexpression are strongly enriched in this molecular class across diverse histologies, including serous carcinoma, carcinosarcoma, and high-grade endometrioid carcinoma. However, accurate assessment remains challenging owing to the presence of distinct basolateral staining patterns and marked intratumoral heterogeneity, both of which differ from canonical breast cancer paradigms and contribute to clinically significant diagnostic discordance. The therapeutic landscape has simultaneously undergone a major transition, moving beyond monoclonal antibodies that require high HER2 expression to antibody-drug conjugates capable of targeting tumors with low-level expression. This shift has established the clinically actionable “HER2-low” category, substantially expanding the population eligible for targeted therapy. More recently, the emerging concept of “HER2-ultralow” expression (defined as immunohistochemistry 0 with faint/incomplete membrane staining in ≤10% of tumor cells) has further challenged traditional binary classification systems and may have therapeutic implications. The efficacy of these agents is driven by the bystander effect, which enables their activity in heterogeneous tumors. This review summarizes the current understanding of HER2 biology in Müllerian cancers, outlines the diagnostic pitfalls and scoring challenges, and discusses evolving therapeutic strategies, with emphasis on integrating molecular classification and optimized testing to ensure accurate patient selection.

Schlagwörter

Stichwörter der Autor:innen

Antibody-drug conjugatesHER2HER2-lowImmunohistochemistryMüllerian malignancies

Autor:innen und Institutionen

  • Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
  • Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India. charanjeetahluwalia70@gmail.com.

Zitieren

APA

Ahuja, S., & Ahluwalia, C. (2026). HER2 in mullerian malignancies: diagnostic challenges and the emerging HER2-low paradigm. Obstetrics & Gynecology Science, 69(6), 418-430. https://doi.org/10.5468/ogs.26195

Vancouver

Ahuja S, Ahluwalia C. HER2 in mullerian malignancies: diagnostic challenges and the emerging HER2-low paradigm. Obstetrics & Gynecology Science. 2026;69(6):418-430. doi:10.5468/ogs.26195

BibTeX
@article{Ahuja2026,
  author = {Ahuja, Sana and Ahluwalia, Charanjeet},
  title = {HER2 in mullerian malignancies: diagnostic challenges and the emerging HER2-low paradigm},
  journal = {Obstetrics & Gynecology Science},
  year = {2026},
  volume = {69},
  number = {6},
  pages = {418--430},
  doi = {10.5468/ogs.26195}
}
Kostenlos starten →